Literature DB >> 1698178

Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.

M J Crain1, W D Waltman, J S Turner, J Yother, D F Talkington, L S McDaniel, B M Gray, D E Briles.   

Abstract

Pneumococcal surface protein A (PspA) has been shown previously to elicit antibodies protective against pneumococcal infection and to be necessary for full pneumococcal virulence in mice. The protein was originally defined by the two mouse monoclonal antibodies Xi64 and Xi126, which together recognized PspA on 14% of pneumococcal isolates. Some PspA molecules reacted with both antibodies, but most reacted with only one or the other. In the present study we demonstrated that PspA is produced by all pneumococci, confirming our hypothesis that there are variants of PspA which are not detected by Xi64 and Xi126. We produced a rabbit antiserum and five additional monoclonal antibodies specific for PspA for these studies. The rabbit antiserum reacted with each of 95 pneumococcal isolated tested, comprising 16 capsular serotypes. One or more of the seven monoclonal anti-PspA antibodies reacted with 95% (53 of 57) of pneumococcal isolates tested. The specificity of the monoclonal and polyclonal antibodies to PspA was confirmed in two ways: (i) by detection of molecules on wild-type pneumococci that are identical in molecular weight to those detected in Western blots (immunoblots) with Xi64 and Xi126 and (ii) by the use of mutants of Streptococcus pneumoniae that fail to produce PspA or that produce a truncated form of PspA. By using the seven monoclonal antibodies, we observed 31 PspA types among the 57 isolates. When the 53 strains reactive with the monoclonal antibodies were analyzed by capsular type as well as by serologic type and molecular weight of PspA, we observed 50 different clonotypes of pneumococci.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698178      PMCID: PMC313652          DOI: 10.1128/iai.58.10.3293-3299.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Identification of a 16,600-dalton outer membrane protein on nontypeable Haemophilus influenzae as a target for human serum bactericidal antibody.

Authors:  T F Murphy; L C Bartos; P A Rice; M B Nelson; K C Dudas; M A Apicella
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Pneumococcal polysaccharide immunization in infants and children.

Authors:  M J Cowan; A J Ammann; D W Wara; V M Howie; L Schultz; N Doyle; M Kaplan
Journal:  Pediatrics       Date:  1978-11       Impact factor: 7.124

3.  Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.

Authors:  D E Briles; C Forman; J C Horowitz; J E Volanakis; W H Benjamin; L S McDaniel; J Eldridge; J Brooks
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

4.  Variation in the molecular weight of PspA (pneumococcal surface protein A) among Streptococcus pneumoniae.

Authors:  W D Waltman; L S McDaniel; B M Gray; D E Briles
Journal:  Microb Pathog       Date:  1990-01       Impact factor: 3.738

5.  Measurement of protein using bicinchoninic acid.

Authors:  P K Smith; R I Krohn; G T Hermanson; A K Mallia; F H Gartner; M D Provenzano; E K Fujimoto; N M Goeke; B J Olson; D C Klenk
Journal:  Anal Biochem       Date:  1985-10       Impact factor: 3.365

6.  Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies.

Authors:  L S McDaniel; G Scott; K Widenhofer; J M Carroll; D E Briles
Journal:  Microb Pathog       Date:  1986-12       Impact factor: 3.738

7.  Protein serotyping of Streptococcus pneumoniae based on reactivity to six monoclonal antibodies.

Authors:  W D Waltman; L S McDaniel; B Andersson; L Bland; B M Gray; C S Eden; D E Briles
Journal:  Microb Pathog       Date:  1988-09       Impact factor: 3.738

8.  Clinical and epidemiologic studies of pneumococcal infection in children.

Authors:  B M Gray; H C Dillon
Journal:  Pediatr Infect Dis       Date:  1986 Mar-Apr

9.  Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).

Authors:  L S McDaniel; J Yother; M Vijayakumar; L McGarry; W R Guild; D E Briles
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

10.  Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae.

Authors:  L S McDaniel; G Scott; J F Kearney; D E Briles
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  100 in total

1.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses.

Authors:  K Overweg; A Kerr; M Sluijter; M H Jackson; T J Mitchell; A P de Jong; R de Groot; P W Hermans
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.

Authors:  Eliane N Miyaji; Daniela M Ferreira; Alexandre P Y Lopes; M Cristina C Brandileone; Waldely O Dias; Luciana C C Leite
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 4.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

5.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

6.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

7.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

8.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

9.  Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.

Authors:  J E Alexander; R A Lock; C C Peeters; J T Poolman; P W Andrew; T J Mitchell; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).

Authors:  Kristopher R Genschmer; Mary Ann Accavitti-Loper; David E Briles
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.